AN2 Therapeutics, Inc.

Ownership Transactions Reported by 19 Insiders

Symbol
ANTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1800 El Camino Real, Suite D, Menlo Park, CA

Insiders trading volume in the past year

AN2 Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Adjuvant Global Health Technology Fund, L.P. 10%+ Owner $45.4M Jan 16, 2024
Braden Michael Leonard 10%+ Owner $5.98M +$1.56M +35.3% Aug 14, 2024
Robin Shane Readnour Director $988K +$406K +69.6% Dec 19, 2024
Paul Eckburg Chief Medical Officer $983K Mar 15, 2024
Joseph S. Zakrzewski Director $739K +$27.8K +3.91% Apr 10, 2025
Kevin Michael Krause Chief Strategy Officer $610K Mar 15, 2024
Kabeer Aziz Director $531K Apr 10, 2025
Eric Easom Chief Executive Officer, Director $461K +$50K +12.2% Feb 26, 2025
Ra Capital Management, L.P. 10%+ Owner $325K -$3.81M -92.1% Aug 9, 2024
Joshua M. Eizen Chief Operating Officer and Chief Legal Officer $235K -$13K -5.23% Feb 26, 2025
Sanjay Chanda Chief Development Officer $107K -$3.97K -3.56% Feb 26, 2025
Lucy Day Chief Financial Officer $106K -$3.97K -3.6% Feb 26, 2025
Stephen David Prior Chief Strategy Officer $82.2K -$2.72K -3.2% Feb 26, 2025
Gilbert Lynn Marks Director $55.7K Apr 10, 2025
Patricia A. Martin Director $8.36K Apr 10, 2025
Melvin K. Spigelman Director Jun 19, 2024
Stephanie Wong Director Jun 19, 2024
Margaret M. FitzPatrick Director Jun 19, 2024
Michael Adrian Nazak Chief Accounting Officer Feb 15, 2023

Recent Insider Transactions by Companies or Individuals for AN2 Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.